



Effect of Ivermectin on Time to Resolution of Symptoms Among  
Adults With Mild COVID-19: A Randomized Clinical Trial | Infectious  
Diseases | JAMA | JAMA Network

**Question** What is the effect of ivermectin on duration of symptoms in adults with mild COVID-19?

**Findings** In this randomized clinical trial that included 476 patients, the duration of symptoms was not significantly different for patients who received a 5-day course of ivermectin compared with placebo (median time to resolution of symptoms, 10 vs 12 days; hazard ratio for resolution of symptoms, 1.07).

**Meaning** The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand effects on other clinically relevant outcomes.

[https://jamanetwork.com/journals/jama/fullarticle/2777389?guestAccessKey=c866888b-46f8-41ab-a866-55beba52862a&utm\\_source=silverchair&utm\\_medium=email&utm\\_campaign=article\\_alert-jama&utm\\_term=mostread&utm\\_content=olf-widget\\_03082021](https://jamanetwork.com/journals/jama/fullarticle/2777389?guestAccessKey=c866888b-46f8-41ab-a866-55beba52862a&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_term=mostread&utm_content=olf-widget_03082021)